Eli Lilly escalated the obesity race with new conference and trial reporting on eloraTZP, an amylin-incretin combination. Lilly said the regimen delivered up to 23.3% weight loss in adults with obesity and type 2 diabetes, aiming to set a higher benchmark than existing GLP-1-based therapies. The same obesity pipeline continues to broaden beyond Lilly’s portfolio. Separate data from Zealand and Roche reinforced that amylin analogs may perform best at a middle dose, while Lilly’s own triple-agonist retatrutide remains a focal point of late-stage development. The cumulative effect is a more crowded metabolic landscape where companies are competing not only on magnitude of weight loss, but on tolerability and whether results translate to patients who also carry diabetes risk. With multiple programs now converging on incretin-and-amylin combinations and next-generation multi-receptor mechanisms, sponsors face tighter expectations for Phase 3 durability and consistency across dosing arms.